Citations

Clear

3501 citation(s) found for "Xu, Timothy".

CLRM-07 RANO 2.0: PROPOSAL FOR AN UPDATE TO THE RESPONSE ASSESSMENT IN NEURO-ONCOLOGY (RANO) CRITERIA FOR HIGH- AND LOW-GRADE GLIOMAS IN ADULTS
Wen, Patrick Y. , Barboriak, Danial, DeGroot, John, Lassman, Andrew B. , Molinaro, Annette M. , Preusser, Mattias, Rahman, Rifaquat , Shankar, Lalitha , Sul, Joohee, Villanueva‐Meyer, Javier , Macdonald, David , Reardon, David A. , Vogelbaum, Michael A. , Chang, Susan M. , Wen, Patrick Yung , Bent, Martin J. van den , Youssef, Gilbert , Cloughesy, Timothy F. , Ellingson, Benjamin M. , Weller, Michael , Galanis, Evanthia , Gilbert, Mark R. , Huang, Raymond Y. , Mehta, Minesh P. , Molinaro, Annette M. , Stupp, Roger , Villanueva-Meyer, Javier E. , Wick, Wolfgang

Mayo Clinic

Neuro-Oncology Advances | August 4, 2023 | Volume: 5 | Issue: Supplement_3 | Pages: iii8-iii8

10.1093/noajnl/vdad070.029 Get It

Abstract The Response Assessment in Neuro-Oncology (RANO) criteria for high-grade gliomas (RANO-HGG) and low-grade gliomas (RANO-LGG) were developed to improve the reliability of response assessment in glioma trials. Over time some limitations of these criteria were identified, and uncertainty emerged regarding integrating features of the modified RANO (mRANO) or the immunotherapy RANO (iRANO) criteria. Informed by data from a cohort of glioblastoma patients and other evaluations of RANO criteria that allowed evaluation of features of the different criteria, we propose updates to the RANO criteria (RANO 2.0). Based on the 2021 WHO classification of gliomas, we recommend a standard set of criteria for both high and low-grade gliomas, to be used for all trials regardless of the treatment modalities being evaluated. In the newly diagnosed setting, the post-radiotherapy MRI, rather than the post-surgical MRI, will be used as the baseline for future comparison. Since the incidence of pseudoprogression is high in the 12 weeks following radiotherapy, continuation of treatment and confirmation of progression during this period with a repeat MRI, or histopathologic evidence of unequivocal recurrent tumor, is required to define tumor progression. However, confirmation scans are not mandatory after this period nor for recurrent tumors. For treatments with a high likelihood of pseudoprogression, mandatory confirmation of progression with a repeat MRI is an option. The primary measurement remains the maximum cross-sectional area of tumor (2-dimensional) but volumetric measurements are an option. For IDH-wildtype glioblastoma, the non-enhancing disease will no longer be evaluated. In IDH-mutated tumors with a significant non-enhancing component, clinical trials may require evaluating both the enhancing and non-enhancing tumor components for response assessment.
AdvanTIG-105: Phase 1b dose-expansion study of ociperlimab (OCI) + tislelizumab (TIS) with chemotherapy (chemo) in patients (pts) with stage IV gastric/gastroesophageal adenocarcinoma (GC/GEJC).
Kim, Sae Hyun , Shiah, Her‐Shyong, Yoon, Harry H. , Zheng, Hao , Zhou, Ziqi , Wang, Ruihua , Lee, Gyeong‐Won , Shim, Byoung Yong , Frentzas, Sophia , Sun, Meili , Clay, Timothy Dudley , Tan, Wei, Ba, Yi

Mayo Clinic

JCO Global Oncology | August 3, 2023 | Volume: 9 | Issue: Supplement_1 | Pages: 31-31

10.1200/go.2023.9.supplement_1.31 Get It

31 Background: T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domains (TIGIT) inhibitor in combination with an anti-programmed cell death protein 1 (PD-1) antibody has shown antitumor activity in solid tumors. AdvanTIG-105 (NCT04047862) is a phase 1/1b open-label study designed to assess the safety and preliminary antitumor activity of OCI, an anti-TIGIT monoclonal antibody (mAb), + TIS, an anti-PD-1 mAb, in pts with unresectable, locally advanced or metastatic solid tumors. In the dose-escalation part, OCI + TIS was well tolerated with preliminary antitumor activity observed, and the recommended phase 2 dose (RP2D) of OCI 900 mg intravenously (IV) every three weeks (Q3W) + TIS 200 mg IV Q3W was established. We report results from the dose-expansion part (GC/GEJC Cohort 9) of the AdvanTIG-105 study. Methods: Eligible pts had histologically/cytologically confirmed stage IV GC/GEJC. Pts were excluded if they had squamous cell, undifferentiated or other histological types of GC, had GC/GEJC with positive HER2 expression, or if they had received any prior therapy for metastatic disease. Pts received either the RP2D of OCI + TIS with oxaliplatin + capecitabine Q3W for 6 cycles (C), followed by maintenance therapy with the RP2D of OCI + TIS, + capecitabine Q3W, or the RP2D of OCI + TIS with cisplatin + 5-fluorouracil Q3W for 6 C. Treatment continued until disease progression, intolerable toxicity, or withdrawal of consent. The primary endpoint was investigator-assessed overall response rate (ORR) per RECIST v1.1. Secondary endpoints included progression-free survival (PFS), duration of response (DoR), disease control rate (DCR) per RECIST v1.1, and safety. Results: As of September 29, 2022, 60 pts with a median age of 61.5 years (range 35-82) were enrolled; 59 were efficacy evaluable. Median study follow-up was 31.1 weeks (range 1.4-78.4). ORR was 50.8% (95% CI: 37.5, 64.1); DCR was 84.7% (95% CI: 73.0, 92.8) with a median DoR of 8.1 months (95% CI: 4.5, not evaluable [NE]). Median PFS was 8.2 months (95% CI: 5.8, NE). In a subgroup analysis, ORR in pts with PD-L1 tumor area positivity (TAP) score ≥5% (n=27) was 59.3% (95% CI: 38.8, 77.6), and 50.0% (95% CI: 30.7, 69.4) in pts with PD-L1 TAP <5% (n=28). All 60 pts reported ≥1 treatment-emergent adverse event (TEAE), the most common being anemia (43.3%) and platelet count decreased (41.7%). In total, 43 pts (71.7%) had ≥grade 3 TEAEs and 28 (46.7%) had serious adverse events. TEAEs leading to discontinuation of TIS and OCI occurred in 5 (8.3%) pts. TEAEs led to death in 2 (3.3%) pts; one event (neutropenic sepsis) was related to chemo, while the other (pulmonary embolism) was not treatment related. Conclusions: OCI 900 mg + TIS 200 mg + chemo was generally well tolerated and showed encouraging antitumor activity in pts with stage IV GC/GEJC. Clinical trial information: NCT04047862 .
Prospective, randomized, double-blind phase 2B trial of the TLPO and TLPLDC vaccines to prevent recurrence of resected stage III/IV melanoma: a prespecified 36-month analysis
Carpenter, Elizabeth Lee, Decar, Spencer Van , McCarthy, Patrick M. , Vreeland, Timothy J. , Valdera, Franklin, Tiwari, Ankur, Hale, Diane F. , Bohan, Phillip Kemp, Hickerson, Annelies T. , Smolinsky, Todd , Thomas, Katryna, Cindass, Jessica L., Hyngstrom, John , Berger, Adam C. , Shaheen, Montaser , Yu, Xianzhong, Wagner, Thomas E., Faries, Mark B. , Peoples, George E. , Van Decar, Spencer , McCarthy, Patrick , Vreeland, Timothy J , Jakub, James, Adams, Alexandra M. , O’Shea, Anne E. , Chick, Robert C. , Clifton, Guy T. , Bohan, Phillip M. Kemp , Jakub, James W. , Sussman, Jonathan

Mayo Clinic

Journal for ImmunoTherapy of Cancer | August 3, 2023 | Volume: 11 | Issue: 8 | Pages: e006665

10.1136/jitc-2023-006665 | PMID 37536936 Get It

Background The tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine is made by ex vivo priming matured autologous dendritic cells (DCs) with yeast cell wall particles (YCWPs) loaded with autologous tumor lysate (TL). The tumor lysate, particle only (TLPO) vaccine uses autologous TL-loaded YCWPs coated with silicate for in vivo DC loading. Here we report the 36-month prespecified analyses of this prospective, randomized, double-blind trial investigating the ability of the TLPO and TLPLDC (±granulocyte-colony stimulating factor (G-CSF)) vaccines to prevent melanoma recurrence in high-risk patients. Methods Patients with clinically disease-free stage III/IV melanoma were randomized 2:1 initially to TLPLDC versus placebo (n=124) and subsequently TLPO versus TLPLDC (n=63). All patients were randomized and blinded; however, the placebo control arm was replaced in the second randomization scheme with another novel vaccine; some analyses in this paper therefore reflect a combination of the two randomization schemes. Patients receiving the TLPLDC vaccine were further divided by their method of DC harvest (with or without G-CSF pretreatment); this was not randomized. The use of standard of care checkpoint inhibitors was not stratified between groups. Safety was assessed and Kaplan-Meier and log-rank analyses compared disease-free (DFS) and overall survival (OS). Results After combining the two randomization processes, a total of 187 patients were allocated between treatment arms: placebo (n=41), TLPLDC (n=103), or TLPO (n=43). The allocation among arms created by the addition of patients from the two separate randomization schemes does not reflect concurrent randomization among all treatment arms. TLPLDC was further divided by use of G-CSF in DC harvest: no G-CSF (TLPLDC) (n=47) and with G-CSF (TLPLDC+G) (n=56). Median follow-up was 35.8 months. Only two patients experienced a related adverse event ≥grade 3, one each in the TLPLDC+G and placebo arms. DFS was 27.2% (placebo), 55.4% (TLPLDC), 22.9% (TLPLDC+G), and 60.9% (TLPO) (p<0.001). OS was 62.5% (placebo), 93.6% (TLPLDC), 57.7% (TLPLDC+G), and 94.6% (TLPO) (p=0.002). Conclusions The TLPO and TLPLDC (without G-CSF) vaccines were associated with improved DFS and OS in this clinical trial. Given production and manufacturing advantages, the efficacy of the TLPO vaccine will be confirmed in a phase 3 trial. Trial registration number NCT02301611 .
Neurofilament Light Chain in Spinal Fluid and Plasma in Multiple System Atrophy – A Prospective, Longitudinal Biomarker Study
Singer, Wolfgang , Schmeichel, Ann M., Sletten, David M., Gehrking, Tonette L., Gehrking, Jade A., Trejo‐Lopez, Jorge , Suarez, Mariana, Anderson, Jennifer K., Bass, Pamela H., Lesnick, Timothy G. , Low, Phillip A. , Suarez, Mariana D., Singer, Wolfgang , Anderson, Jennifer K.

Mayo Clinic

No container title available | August 1, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-3201386/v1 | PMID 37577499 Get It

Abstract Purpose There is a critical need for reliable diagnostic biomarkers as well as surrogate markers of disease progression in multiple system atrophy (MSA). Neurofilament light chain (NfL) has been reported to potentially meet those needs. We therefore sought to explore the value of NfL in plasma (NfL-p) in contrast to CSF (NfL-c) as diagnostic marker of MSA, and to assess NfL-p and NfL-c as markers of clinical disease progression. Methods Well-characterized patients with early MSA (n=32), Parkinson’s disease (PD, n=21), and matched controls (CON, n=15) were enrolled in a prospective, longitudinal study of synucleinopathies with serial annual evaluations. NfL was measured using a high sensitivity immunoassay, and findings were assessed by disease category and relationship with clinical measures of disease progression. Results Measurements of NfL-c were highly reproducible across immunoassay platforms (Pearson,r=0.99), while correlation between NfL-c and -p was only moderate (r=0.66). NfL was significantly higher in MSA compared to CON and PD; the separation was essentially perfect for NfL-c, but there was overlap, particularly with PD, for NfL-p. While clinical measures of disease severity progressively increased over time, NfL-c and -p remained at stable elevated levels within subjects across serial measurements. Neither change in NfL nor baseline NfL were significantly associated with changes in clinical markers of disease severity. Conclusions These findings confirm NfL-c as faithful diagnostic marker of MSA, while NfL-p showed less robust diagnostic value. The significant NfL elevation in MSA was found to be remarkably stable over time and was not predictive of clinical disease progression.
Advancing specificity in delirium: The delirium subtyping initiative
Bowman, Emily M L , Fiest, Kirsten M. , Girard, Timothy D. , Jackson, Thomas , LaHue, Sara C. , MacLullich, Alasdair M. J. , McAuley, Daniel F. , Potter, Kelly , Sinha, Pratik , Slooter, Arjen J. C. , Sweeney, Aoife , Tieges, Zoë , Dellen, Edwin van , Wilcox, M. Elizabeth , Cunningham, Emma , Lindroth, Heidi L., Girard, Timothy D , MacLullich, Alasdair M J , Slooter, Arjen J C , Brummel, Nathan E. , Caplan, Gideon A. , Cunningham, Colm M. , Evered, Lisbeth Anne , Lindroth, Heidi , Oh, Esther S , Oldham, Mark , Page, Valérie , Pandharipande, Pratik , Zetterberg, Henrik

Mayo Clinic

Alzheimer's & Dementia | July 31, 2023 | Volume: 20 | Issue: 1 | Pages: 183-194

10.1002/alz.13419 | PMID 37522255 Get It

AbstractBACKGROUNDDelirium, a common syndrome with heterogeneous etiologies and clinical presentations, is associated with poor long‐term outcomes. Recording and analyzing all delirium equally could be hindering the field's understanding of pathophysiology and identification of targeted treatments. Current delirium subtyping methods reflect clinically evident features but likely do not account for underlying biology.METHODSThe Delirium Subtyping Initiative (DSI) held three sessions with an international panel of 25 experts.RESULTSMeeting participants suggest further characterization of delirium features to complement the existing Diagnostic and Statistical Manual of Mental Disorders Fifth Edition Text Revision diagnostic criteria. These should span the range of delirium‐spectrum syndromes and be measured consistently across studies. Clinical features should be recorded in conjunction with biospecimen collection, where feasible, in a standardized way, to determine temporal associations of biology coincident with clinical fluctuations.DISCUSSIONThe DSI made recommendations spanning the breadth of delirium research including clinical features, study planning, data collection, and data analysis for characterization of candidate delirium subtypes.Highlights Delirium features must be clearly defined, standardized, and operationalized. Large datasets incorporating both clinical and biomarker variables should be analyzed together. Delirium screening should incorporate communication and reasoning.
Surgical Site Infections in Open and Laparoscopic Operations in Rooms With Open-floor Drainage Systems
Durant, Adri , Whitney, Madeline , Larson, Michelle A., Shah, Paras , Humphreys, Mitchell R. , Etzioni, David A. , Tyson, Mark D. , Durant, Adri M, Whitney, Madeline A, Chang, Yu‐Hui H., Chang, Yu‐Hui , Lyon, Timothy D.

Mayo Clinic

Urology Practice | July 27, 2023 | Volume: 10 | Issue: 6 | Pages: 622-629

10.1097/upj.0000000000000434 | PMID 37498642 Get It

The Added Power of Synthetic Control Groups: Challenging Conventional Wisdom and Trial Design in Idiopathic Pulmonary Fibrosis Research
Dempsey, Timothy , Dempsey, Timothy M , Limper, Andrew H.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | July 27, 2023 | Volume: 208 | Issue: 5 | Pages: 515-516

10.1164/rccm.202307-1174ed | PMID 37499091 Get It

Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel
Paiva, Bruno , Manrique, Irene , Campbell, Timothy , Kazanecki, Christian C. , Martin, Nathan , Anderson, Larry D. , Berdeja, Jesús G. , Lonial, Sagar , Raje, Noopur , Munshi, Nikhil C. , Kaiser, Shari M. , Rytlewski, Julie , Campbell, Timothy , Kazanecki, Christian C , Martin, Nathan , Anderson, Larry D , Berdeja, Jesús G , Lonial, Sagar , Raje, Noopur S , Lin, Yi , Moreau, Philippe , San-Miguel, Jesus , Munshi, Nikhil C , Kaiser, Shari M , Paiva, Bruno , Lin, Yi , Moreau, Philippe , Miguel, Jesús F. San

Mayo Clinic

Blood Cancer Discovery | July 24, 2023 | Volume: 4 | Issue: 5 | Pages: 365-373

10.1158/2643-3230.bcd-23-0044 | PMID 37486974 Get It

Abstract The role of measurable residual disease (MRD) in multiple myeloma patients treated with chimeric antigen receptor (CAR) T cells is uncertain. We analyzed MRD kinetics during the first year after idecabtagene vicleucel (ide-cel) infusion in 125 relapsed/refractory multiple myeloma patients enrolled in KarMMa. At month 1 after ide-cel, there were no differences in progression-free survival (PFS) between patients in less than complete response (CR) versus those in CR; only MRD status was predictive of significantly different PFS at this landmark. In patients with undetectable MRD at 3 months and beyond, PFS was longer in those achieving CR versus &lt;CR. Persistent MRD in the 10−6 logarithmic range and reappearance of normal plasma cells in MRD-negative patients were associated with inferior PFS. This study unveils different prognostic implications of serological and MRD response dynamics after ide-cel and suggests the potential value of studying the reappearance of normal plasma cells as a surrogate of loss of CAR T-cell functionality. Significance: This is one of the first studies evaluating the impact of CR and MRD dynamics after CAR T therapy in relapsed/refractory multiple myeloma. These data help interpret the prognostic significance of serological and MRD responses at early and late time points after CAR T-cell infusion. See related commentary by Landgren and Kazandjian, p. 346 . This article is featured in Selected Articles from This Issue, p. 337
Author response: Mitochondrial MICOS complex genes, implicated in hypoplastic left heart syndrome, maintain cardiac contractility and actomyosin integrity
Birker, Katja , Kalvakuri, Sreehari , Grossfeld, Paul , Colas, Alexandre R. , Bodmer, Rolf , Ge, Shuchao , Kirkland, Natalie J. , Theis, Jeanne L. , Marchant, James , Fogarty, Zachary C. , Missinato, Maria A , Engler, Adam Jeffrey , Ocorr, Karen , Nelson, Timothy J. , Olson, Timothy M. , Vogler, Georg

Mayo Clinic

No container title available | July 21, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7554/elife.83385.sa2 Get It

Rotator Cuff Repair with Knotless All‐Suture Medial Row Anchors and Biceps Autograft Augmentation
Hassebrock, Jeffrey D. , McCarthy, Timothy Patrick , Sylvia, Stephen M. , Stokes, Daniel J. , Shinsako, Kevin K. , Tokish, John M. , Hassebrock, Jeffrey D , McCarthy, Timothy P., Frank, Rachel M

Mayo Clinic

Arthroscopy Techniques | July 17, 2023 | Volume: 12 | Issue: 8 | Pages: No page available

10.1016/j.eats.2023.04.005 | PMID 37654888 Get It

Abstract Incomplete healing and/or functional failure following rotator cuff tear repair remains a challenging problem for both patients and surgeons. Augmentation strategies are growing to increase healing through biologic and mechanical mechanisms to improve functional results after arthroscopic rotator cuff repair. The majority of currently described augmentation techniques use allograft tissue. An alternative, low‐cost, autograft option for augmentation is the use of the long head of biceps tendon autograft as a free functional graft. Here, we describe the use of autograft biceps tendon as a viable option for augmentation of double‐row rotator cuff repair with knotless all‐suture suture anchors. Technique Video video See video under supplementary data.